VYNE Therapeutics Inc.
VYNE
$0.36
-$0.01-2.11%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
11/8/2025
-
Ticker Report
11/7/2025
-
TipRanks Financial Blog
11/6/2025
-
Zacks Investment Research
11/6/2025
-
GuruFocus
11/6/2025
-
The Fly
11/6/2025
-
Globe Newswire
10/10/2025
-
Ticker Report
9/12/2025
-
TipRanks Financial Blog
9/10/2025
-
Ticker Report
8/16/2025
-
Simply Wall St
8/14/2025
-
Zacks Investment Research
8/14/2025
-
GuruFocus
8/14/2025
-
Fool.com Headlines
8/14/2025
-
GuruFocus
8/14/2025
-
TipRanks Financial Blog
8/14/2025
-
The Fly
8/14/2025
-
Globe Newswire
8/12/2025
-
Zacks Investment Research
8/11/2025
-
Zacks Investment Research
8/6/2025
-
Zacks Investment Research
8/1/2025
-
Ticker Report
7/30/2025
-
The Fly
7/30/2025
-
GuruFocus
7/30/2025
-
GuruFocus
7/30/2025
-
The Fly
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Thursday, November 6, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Mar 2 and 6 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
800 775 7936
Address
685 Route 202/206 N
Bridgewater, NJ 08807
Bridgewater, NJ 08807
Country
Year Founded
Business Description
Sector
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company’s lead program is...
more